Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Timperley, J.
Right arrow Articles by Banning, A.P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Timperley, J.
Right arrow Articles by Banning, A.P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Q J Med 2002; 95: 706-707
© 2002 Association of Physicians

Correspondence

New antiplatelet agents and prosthetic heart valves

J. Timperley, N.R.A. Clarke and A.P. Banning

Cardiology Department, Oxford Radcliffe Hospital NHS Trust, John Radcliffe Hospital, Oxford email: cardiology.registrars@orh.nhs.uk (Dr Timperley)

The first 10% of the full text of this article appears below.

Sir,

Despite advances in prosthetic valve design, patients who undergo valve replacement are at risk of arterial thromboembolism and valve thrombosis. We present four cases where new antiplatelet agents have been used.

A 61-year-old man with aortic valve endocarditis underwent early mechanical valve replacement. He developed mitral regurgitation and an aortic-right-atrial fistula requiring surgical closure and mitral valve replacement. He had . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?